- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06922175
도달 범위 : RWE 후 향적 연구는 건강 관리 자원 활용에 대한 테노 바메이트 영향을 평가하는 후 향적 연구
통제되지 않은 초점 발작 관리에서 Cenobamate의 건강 관리 자원 활용 (HCRU)의 후 향적 평가- 회고 적, 차트 검토 연구
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
연구 개요
상태
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Netherlands
-
Heeze, Netherlands, 네덜란드
- Kempenhaeghe - Academisch Centrum voor Epilepsie
-
-
-
-
Germany
-
Freiburg im Breisgau, Germany, 독일
- Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
-
Hamburg, Germany, 독일
- Epileptologicum
-
Kork, Germany, 독일
- Diakonie Kork, Epilepsiezentrum
-
-
-
-
Switzerland
-
Zurich, Switzerland, 스위스
- Department of Neurology, University Hospital Zurich
-
-
-
-
Spain
-
Barcelona, Spain, 스페인
- Epilepsy Unit - Neurology Department Valle de Hebron Hospital
-
Madrid, Spain, 스페인
- Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
-
Valencia, Spain, 스페인
- Consorcio Hosp. General Universitario Valencia
-
-
-
-
UK
-
Glasgow, UK, 영국
- Institute of Neurosciences NHS Greater Glasgow and Clyde
-
Wolverhampton, UK, 영국
- Epilepsies - The Royal Wolverhampton NHS Trust
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.
설명
Inclusion Criteria:
- Male and female patients of any ethnic origin ≥18 years old at index date;
- Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
- Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
- Patients with at least 6 months of data coverage in the medical records prior to the index date;
- Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
- Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.
Exclusion Criteria:
- Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
- Patients who started cenobamate within an EAP;
- Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
- Patients with specific syndrome (e.g. LGS and Dravet);
- Pregnancy or lactation;
- Patients without self-judgement ability;
- Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
- Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: RETROSPECTIVE
코호트 및 개입
그룹/코호트 |
|---|
|
Adult patients affected by epilepsy with focal-onset seizures
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits; |
0-12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
기간: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected; |
0-12 months
|
|
Effectiveness of cenobamate used as adjunctive therapy
기간: 0-12 months
|
To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days); |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
기간: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
기간: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
기간: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected. |
0-12 months
|
|
Safety of cenobamate used as adjunctive therapy
기간: 0-12 months
|
To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study. |
0-12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .